BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20618370)

  • 1. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
    Van Meurs T; Van Doorn R; Kirtschig G
    Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod.
    Ramsdell AM; Zeitouni N
    Dermatol Surg; 2009 Feb; 35(2):287-90. PubMed ID: 19215272
    [No Abstract]   [Full Text] [Related]  

  • 3. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
    Lorentzen HF; Weismann K
    Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.
    Borucki U; Metze D
    Dermatology; 2003; 207(3):326-8. PubMed ID: 14571081
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
    Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
    J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
    Kirtschig G; van Meurs T; van Doorn R
    Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
    Powell AM; Robson AM; Russell-Jones R; Barlow RJ
    Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
    Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
    Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lentigo maligna treated with 5% imiquimod cream].
    Martín T; Ojeda A; Martínez S; Vera A
    Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod immunotherapy in the management of lentigo maligna.
    Powell AM; Russell-Jones R; Barlow RJ
    Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Swetter SM; Chen FW; Kim DD; Egbert BM
    J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical imiquimod therapy for lentigo maligna.
    Mahoney MH; Joseph MG; Temple C
    Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
    Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
    Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
    Woodmansee CS; McCall MW
    Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.